We are live on ! Find out more

PTC Therapeutics

PTCT

Market cap $6.13B

73.47 USD

+2.41

3.39%

At close Updated Aug 25, 4:00 PM EDT

Pre-market

After hours

73.47

0.00

0%

1 day

3.39%

5 days

-0.34%

1 month

-3.07%

3 months

8.6%

6 months

8.43%

Year to date

-4.26%

1 year

49.03%

5 years

81.36%

10 years

826.48%

About: PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Employees: 991

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 36%

Neutral 48%

Negative 16%

PTC Therapeutics Announces New Sephience™ (sepiapterin) Data Reinforcing Broad Patient Benefits Including Sustained Metabolic Control and Diet Liberalization as well as Consistent Favorable Safety Profile

– 17 abstracts and presentations planned at SSIEM Symposium – – Real-world evidence demonstrates significant diet liberalization achieved with Sephience while maintaining target blood Phe levels – – Continued evidence of meaningful benefit across all patient subgroups – WARREN, N.J., Aug. 24, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that multiple Sephience™ (sepiapterin) scientific data presentations will be featured at the 2026 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium, taking place in Helsinki, Finland, from Aug. 25-28.

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

PTC Therapeutics offers a compelling risk-reward profile, with its valuation not fully reflecting the upside from Sephience and potential ST-920 approval. Sephience, PTCT's lead asset, has driven rapid revenue growth, accounting for 63% of product revenue and expanding across major global markets. ST-920, acquired from Sangamo, is a late-stage gene therapy for Fabry Disease; FDA approval could significantly enhance PTCT's valuation.

PTC Therapeutics: An Acquisition Which Could Unlock Massive Potential

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal

PTC Therapeutics NASDAQ: PTCT plans to acquire the ST-920 Fabry disease gene therapy asset through a competitive bankruptcy auction, positioning the company to add a potential one-time treatment to its rare disease portfolio while using its existing global commercial and regulatory infrastructure.

PTC Therapeutics Targets Fabry Gene Therapy in $111M Bankruptcy Auction Deal

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

PTC Therapeutics Inc. (NASDAQ:PTCT) on Wednesday said it is expanding its rare disease portfolio through the planned acquisition of the ST-920 Fabry disease program from Sangamo Therapeutics in a competitive bankruptcy auction.

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J.

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

Zacks Investment Research

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks You'll Regret Missing This Quarter

Zacks Investment Research

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

See News Rankings

Price charts implemented using Lightweight Charts™